Synjardy® offers the convenience of Jardiance® and metformin in one tablet1A,2D

brand_logo
lady img
  • Metformin and lisinopril
  • HbA1c not at goal: treatment escalation needed
  • Typically presents with high blood pressure
  • Appreciates low pill burden

For patients like Jane with multiple risk factors, ease the stress about adding more medications

Reduction in: SYNJARDY*2,3 Janumet4
(sitagliptin/metformin HCI)
Glucose levels synjardy_table_dot img3f synjardy_table_dot img4a
Weight synjardy_table_dot img3b x4b,c
Blood pressure synjardy_table_dot img3c -
SYNJARDY contains JARDIANCE, which also provided patients with T2D and CV disease with reduction in†‡ll:
Risk of CV death synjardy_table_dot img2a x4d
Risk of hospitalisation for HF synjardy_table_dot img2a x4d

†Selected evidence from T2D CVOTs for T2D patients with CV risk.

Comparison of studies should be interpreted with caution due to differences in study design, populations, and methodology. Depicted are the primary endpoint of reduction in glucose levels and selected secondary and exploratory endpoints. 

No head-to-head comparisons of SYNJARDY and sitagliptin/metformin in clinical trials.

Janumet is a registered trademark of Merck & Co., Inc.

  • synjardy_table_dot img

    = benefit shown

  • x

    = no benefit shown

  • -

    = no evidence available

Amplify adherence benefits for your patients with single-pill combinations5A

2IN1

May help promote adherence5A

Poor adherence is associated with higher:5B

  • Costs
  • Mortality and hospitalisation rates

Increasing adherence is associated with greater efficacy6A

  • Improving adherence by 10% has been shown to reduce HbA1c by an additional 0.1% compared with non-adherent patients

synjardy®contains empagliflozin and metformin in a single tablet1A Available Synjardy® doses

2X DAILY
EMPAGLIFLOZIN/METFORMIN

single_tablet img

With meals, twice daily1b,c

The dosage should be individualised on the basis of the patient’s current regimen, effectiveness, and tolerability, while not exceeding the recommended daily dose.1b,c

synjardy_meals img

Patients switching from separate tablets of empagliflozin (10 mg or 25 mg total daily dose) and metformin to SYNJARDY® should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin. The maximum recommended daily dose is 25/2000 mg.1b,e

ONLY Synjardy® combines the benefits of Jardiance® and metformin in ONE convenient pill1A

lady img
  • Significant reduction in HbA1c, weight and blood pressure3a,b,c
  • Different dosing options to individualise treatment1a
  • Demonstrated safety profile3d
  • 38% relative risk reduction in CV death and 35% relative risk reduction in HHF2a

SYNJARDY® SIGNIFICANTLY REDUCED HbA1c

UP TO 4.6% MEAN HbA1c REDUCTION FROM BASELINE MORE THAN 10%3E,F

Synjardy® contains Jardiance® the only anti-diabetic agent registered in South Africa for the reduction of CV Death risk in patients with T2D and established CV disease2C,D

synjardy_logo img
synjardy_jardiance_logo img

CV Death

38%Relative Risk Reduction2

2.2%Absolute Risk Reduction

HR-0.62 (95% CI: 049-0.77)
p<0.0012

CARDIOPROTECTION results from EMPA-REG OUTCOME Trial2b

References: 1. Synjardy Professional information. Ingelheim Pharmaceuticals (Pty) Limited. October 2020. 2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME® Investigators. Empagliaozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. 3. Hadjadj S, et al. Diabetes Care 2016; 2016 Oct;39(10):1718-28. doi: 10.2337/dc16-0522. 4. Janumet® SmPC (Summary of product characteristics). 5. García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175-194. 6. Rozenfeld Y, Hunt JS, Plauschiant C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71-75.

South Africa. S4 SYNJARDY® 5/500 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 500 mg. Reg. No. 49/21.2/0915; SYNJARDY® 5/850 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 850 mg. Reg. No. 49/21.2/0916; SYNJARDY® 5/1000 mg: Each film-coated tablet contains empagliflozin 5 mg and metformin HCl 1000 mg. Reg. No. 49/21.2/0917; SYNJARDY® 12.5/500 mg: Each film-coated tablet contains empagliflozin 12.5 mg and metformin HCl 500 mg. Reg. No. 49/21.2/0918; SYNJARDY® 12.5/850 mg: Each film-coated tablet contains empagliflozin 12.5 mg and metformin HCl 850 mg. Reg. No. 49/21.2/0919. SYNJARDY® 12.5/1000 mg: Each film-coated tablet contains empagliflozin 12.5 mg and metformin HCl 1000 mg. Reg. No. 49/21.2/0920. NAMIBIA. NS2. Synjardy 5/500 mg. 16.21.2/0210; SYNJARDY® 5/850 mg. 16.21.2/0211; SYNJARDY® 5/1000 mg 16.21.2/0212; SYNJARDY® 12.5/500 mg 16.21.2/0213; SYNJARDY® 12.5/850 mg 16.21.2/0214; SYNJARDY® 12.5/1000 mg 16.21.2/0215.

For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, Suite 1, Building 4, 2nd Floor, Waterfall Corporate Campus, 74 Waterfall Drive, Midrand, 2066. Cpy Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-101593 Expiry Date: February 2024.